MedTrace Logo

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

NCT04201197 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-07-24

Study results available
· View outcomes & findings →

Summary

This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6), and midazolam (CYP3A).

Conditions

  • Drug-Interactions

Interventions

DRUG

Inje cocktail

Acute drug exposure

DRUG

THC Cannabis extract

Acute drug exposure

DRUG

THC/CBD Cannabis Extract

Acute drug exposure

Sponsors & Collaborators

  • Washington State University

    collaborator OTHER

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Ryan Vandrey, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-10
Primary Completion
2022-03-16
Completion
2022-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201197 on ClinicalTrials.gov